Treatment of diseases or disorders using placental stem cells

A method of treating an individual who has a disease or disorder, comprising administering to the individual therapeutically effective amount of isolated human placental stem cells, wherein said placental stem cells are:

• CD34−, CD10+, CD29+, CD44+, CD45−, CD54+, CD90+, SH3+, SH4+, SSEA3−, SSEA4−, wherein OCT-4 is octamer binding protein 4;
• OCT-4+, CD34−, SSEA3− and SSEA4−;
• OCT-4+ and CD34−, and additionally SH3+ or SH4+;
• or
• CD34− and one or more of CD29+, CD45−, CD90+, SH2+, SH3+, SH4+, or MHC Class II−;
• and wherein said disease or disorder is inflammation, multiple sclerosis, cardiac arrest, myocardial infarction, cerebral palsy, Alzheimer's disease, Parkinson's disease, retinal ischemia, a burn or wounding of the skin, injury to an organ, a seizure disorder, hypotension, cerebral palsy, a neurodegenerative disease, Leigh disease, AIDS dementia, amyotrophic lateral sclerosis, ischemic renal disease, heart-lung bypass, glaucoma, Tay-Sachs disease, Niemann-Pick disease, Fabry disease, Gaucher's disease, Hunter's syndrome, Hurler's syndrome, adrenoleukodystrophy, cystic fibrosis, a glycogen storage disease, hypothyroidism, sickle cell anemia, Pearson syndrome, Pompe's disease, phenylketonuria (PKU), a porphyria, maple syrup urine disease, homocystinuria, mucoplysaccharidenosis, chronic granulomatous disease, tyrosinemia, or Tay-Sachs disease.